An Open-label, DDI Study to Investigate the Effects of Amlitelimab on the PK of Selected Cytochrome P450 Substrates

Sponsor
Sanofi
Study ID
NCT06686628
Phase
PHASE1
Status
Completed

Conditions

  • Dermatitis Atopic

Eligibility Criteria

Sex
ALL
Age
18 Years - 65 Years
Healthy Volunteers
Not accepted

Interventions

  • Amlitelimab — DRUG
    Pharmaceutical form: Injection solution Route of administration: SC injection
  • Midazolam — DRUG
    Pharmaceutical form: Solution Route of administration: Oral
  • Caffeine — DRUG
    Pharmaceutical form: Tablet Route of administration: Oral
  • Metoprolol — DRUG
    Pharmaceutical form: Tablet Route of administration: Oral
  • Omeprazole — DRUG
    Pharmaceutical form: Capsule Route of administration: Oral
  • Warfarin — DRUG
    Pharmaceutical form: Tablet Route of administration: Oral

Study Details

This is an open-label, single group, 2-period, Phase 1, single-sequence study. The study duration will be up to 342 days. The treatment period will be up to Week 29, where Week 29 is defined as End of Treatment (last amlitelimab administration at Week 25). The number of visits will be 23 or 21 visits for participants who decide to continue amlitelimab therapy in the long-term extension study LTS17367 (RIVER-AD) study.

Key Dates

Start date
Nov 20, 2024
Status verified
Apr 2026
Primary completion
Nov 21, 2025
Completion
Apr 2, 2026

Study Design

Enrollment
23 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Amlitelimab and CYP substrates
    A single oral dose of a CYP450 substrates cocktail which will include caffeine, metoprolol, midazolam, omeprazole, and warfarin will be administered. A single dose of amlitelimab will then be administered on several days. A single oral dose of CYP450 substrates cocktail in combination with the last single dose of amlitelimab.

Primary Outcome Measure

AUC and AUClast for CYP substrates [ Time Frame: Baseline (Day 1 to Day 8) and Day 176 to Day 183 ]

Related Studies